🔬
analysis

Can CSF p-tau217 normalization serve as a reliable surrogate endpoint for determining donanemab cessation thresholds?

🔬 Analysis Details
Can CSF p-tau217 normalization serve as a reliable surrogate endpoint for determining donanemab cessation thresholds?
completed neurodegeneration 🧪 7 hypotheses 📓 0 notebooks $0.00
Can CSF p-tau217 normalization serve as a reliable surrogate endpoint for determining donanemab cessation thresholds?
Gap: gap-debate-20260417-033134-20519caa
🔬 View Full Analysis →📊 Report ↗
View on SciDEX ↗